



Andrew L. Salzman

MD

PROFESSIONAL SUMMARY

40 years' experience in the biotech/pharmaceutical industry, having initiated and built several companies. Harvard-trained, board-certified in pediatrics, specifically critical care and infectious disease. A significant achievement was the discovery and development of the first PARP inhibitor for the treatment of cancer. Instrumental in identifying and developing the first adenosine 1 receptor agonist for use in ophthalmology.

CONTACT

+1 – 215-648-1208 Ext. 712

ASalzman@thebrackengroup.com

[LinkedIn Profile](#)

www.thebrackengroup.com

EDUCATION

Bachelor of Arts 1979

Yale College; Psychology
Magna Cum Laude

MD 1983

Harvard Medical School

ACADEMIC MEDICAL POSTIONS

University of Cincinnati College of Medicine 1997 - 1999

Assistant Professor of Pediatrics and
Molecular and Cellular Physiology

**Division of Critical Care Medicine,
Children's Hospital Medical Center**

Founding Director; 1994-1998

Assistant Professor of Pediatrics

1994 - 1997

MEDICAL BOARD CERTIFICATION

American Board of Pediatrics

#35899; 1987

**Diplomat; American Academy of
Pediatrics, Critical Care Medicine**

1994

PROFESSIONAL EXPERIENCE

2021 –
Present

The Bracken Group
Partner

2008 –
Present

NanoClinical, LTD

Founder, V.P. Quality and Operations

- Founded and leads a 90-person Israeli company to provide capital and operational services to global biotechnology, medical device, and pharmaceutical enterprises
- Leads consulting services to start-up, mid-sized pharmaceutical and strategic pharmaceutical and agrochemical firms
- Built and manages a 16,000-square-foot research and development facility in Katzrin
- Brokered venture capital raises of \$7 million and received contractual research service orders for \$90 million in the fields of medicinal chemistry, in vitro and in vivo pharmacology, scale-up process research and manufacturing, ADME/PK investigation, and clinical trials design and management.

2008 –
Present

Salzman Group, Inc. (Formerly Radikal Therapeutics, Inc.)
Chairman, Founder, Owner

- Leads a 25-person Massachusetts pharmaceutical biotechnology firm that invents and develops therapeutics for inflammation, reperfusion injury, cardiovascular, and auto-immune disease.
- Invented 7 pre-clinical pharmaceutical assets, including a novel thioredoxin mimetic for treatment of acute lung injury, a novel potassium-ATP channel opener for treatment of hemorrhagic shock, and a novel redox degradation catalyst and nitric oxide donor for treatment of acute lung injury.
- Led raises totaling \$111 million.
- Built out operations in a 9,000-square-foot lab in Massachusetts.

2014 –
2018

Salzman Investments, Ltd. (Formerly Salzman Lovelace Investments Ltd.)

Chairman, Founder

- A biotechnology firm focused on discovery and development of Resolvins, a novel class of anti-inflammatory lipid mediators intended for inhalational treatment of cystic fibrosis, asthma, and chronic obstructive pulmonary disease. Advanced Phase 2 ready asset by developing a novel efficient synthetic route for large scale production of Resolvin E1.

2007 –
Present

Salzman Group Pty Ltd.

Chairman, Founder

2018 –
Present

Herring Creek Pharmaceuticals, Inc.

Chairman, Founder

2021 –
Present

SyncaLabs AG

Chairman, Founder, Owner

2018 –
2020

AOX Pharma

Chairman, Founder

FELLOWSHIPS

- **Beth Israel Hospital;** National Institute of Health Trauma Fellow; 1993 – 1994
- **Massachusetts General Hospital;** National Institute of Health Trauma Fellow; 1992 – 1993
- **University of Massachusetts Medical Center;** National Institute of Health Trauma Fellow; 1991 – 1992
- **Division of Neonatal and Pediatric Intensive Care, Massachusetts General Hospital;** Clinical Fellow in Neonatology; 1990 – 1992
- **Division of Neonatal and Pediatric Intensive Care, Massachusetts General Hospital;** Clinical Fellow in Pediatric Critical Care Medicine; 1990 – 1992
- **Division of Infectious Diseases, Children’s Hospital Medical Center;** Clinical Fellow in Pediatric Medicine; 1987 – 1989
- **Department of Chemical Immunology, Macarther Center for Tropical Disease, Weizman Institute of Science;** Whitman – Richardson Harvard Medical School Fellow; 1986 – 1987
- **Babies Hospital, Columbia – Presbyterian Medical Center ,** Pediatric Resident; 1984 – 1986
- **Babies Hospital, Columbia – Presbyterian Medical Center;** Pediatric Intern; 1983 – 1984
- **Goethe Institute;** German Academic Exchange Institute Fellow; 1980
- **Department of Child Psychiatry Hospital for Sick Children;** Psychiatric Research Fellow; 1977-1978

May 2014 –
Jul 2017

Kalytera Therapeutics, Inc.; Kalytera Therapeutics, Ltd.
Founder, Chief Executive Officer, Chief Medical Officer

2015 –
2018

Tisbury Pharmaceuticals
Chairman, Founder

2012 –
2017

Lovelace Biomedical Research Institute
Senior Fellow and Founding Director of Drug Development

2010 –
2013

Orphan Technologies, Inc.
Chairman, Founder, General Partner

2008 –
2012

Luria Scientific Industries Limited
Chairman, Founder, Owner

2008 –
2012

Neopharm Life Sciences Ventures, Ltd.
Chairman, Founder, Owner, General Partner

MEDICAL LICENSURE

South Carolina #19878
Ohio #66755
Massachusetts #59180
New York State #162426

LANGUAGES AND AWARDS

Fluency in English, German
Proficiency in French, Hebrew, Swiss-German
Yale University German Award, 1979
Society of Critical Care Medicine Educational Scholarship Award, 1993

SCIENTIFIC ACHIEVEMENTS AND PUBLICATIONS

170+ Publications, 46 Patents, 30+ Major Scientific and Medical Accomplishments